Photo of Richard T. Maziarz, MD

Richard T. Maziarz MD

Dr. Maziarz specializes in treating bone marrow transplantation and blood cancers. His research interests cover how the immune system recovers after a bone marrow transplant and how the immune system works to fight cancer. Dr. Maziarz sees patients with leukemia, lymphoma and graft vs. host disease and patients who are being treated with immune system therapies.

Education

  • M.D., Harvard Medical School, 0 0 1979
  • Residency:

    • University Hospitals of Cleveland, 1981
  • Fellowship:

    • Immunology, Dana-Farber Cancer Institute, 1985
  • Certifications:

    • American Board of Internal Medicine (internal medicine), 1982

Memberships and associations

  • American Society of Hematology

Publications

  • "Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory waldenström macroglobulinemia : Evidence for a graft-versus-lymphoma effect." Haematologica  In: , Vol. 103, No. 6, 03.06.2018, p. e252-e255.
  • "A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT)." Bone Marrow Transplantation  In: , 20.02.2018, p. 1-9.
  • "Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma : An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes." Clinical Lymphoma, Myeloma and Leukemia  In: , Vol. 18, No. 1, 01.01.2018, p. e41-e50.
  • "Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016." Biology of Blood and Marrow Transplantation In: , 01.01.2018.
  • "Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials." Biology of Blood and Marrow Transplantation In: , 01.01.2018.
  • "Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia." Biology of Blood and Marrow Transplantation  In: , 01.01.2018.
  • "Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma : Long-Term Follow-Up Report." Biology of Blood and Marrow Transplantation In: , 01.01.2018.
  • "Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation." Journal of Clinical Oncology  In: , Vol. 35, No. 36, 20.12.2017, p. 4003-4011.
  • "Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma." Leukemia and Lymphoma In: , 04.12.2017, p. 1-6.
  • "Allogeneic stem cell transplantation in fully MHC-matched Mauritian cynomolgus macaques recapitulates diverse human clinical outcomes." Nature Communications In: , Vol. 8, No. 1, 1418, 01.12.2017.
  • "Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma." Leukemia and Lymphoma  In: , 22.09.2017, p. 1-10.
  • "Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma : a randomised, double-blind, phase 3 trial." The Lancet Haematology In: , Vol. 4, No. 9, 01.09.2017, p. e431-e442.
  • "Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States." Blood  In: , Vol. 130, No. 9, 31.08.2017, p. 1156-1164.
  • "Concise review : The high cost of high tech medicine: Planning ahead for market access." Stem Cells Translational Medicine In: , Vol. 6, No. 8, 01.08.2017, p. 1723-1729.
  • "Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma." Haematologica In: , Vol. 102, No. 7, 26.06.2017, p. e261-e265.
  • "Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia." Biology of Blood and Marrow Transplantation  In: , Vol. 23, No. 5, 01.05.2017, p. 767-775.
  • "Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes." Journal of Clinical Oncology In: , Vol. 35, No. 11, 10.04.2017, p. 1154-1161.
  • "Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies : A CIBMTR study." Bone Marrow Transplantation In: , Vol. 52, No. 2, 01.02.2017, p. 270-278.
  • "Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma." Clinical Lymphoma, Myeloma and Leukemia  In: , 01.01.2017.
  • "Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation : Long-term Follow-up of a Randomized Clinical Trial." JAMA oncology  In: , Vol. 2, No. 12, 01.12.2016, p. 1583-1589.
  • "The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes." Haematologica  In: , Vol. 101, No. 11, 31.10.2016, p. 1426-1433.
  • "Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma : A CIBMTR Analysis." Biology of Blood and Marrow Transplantation  In: , Vol. 22, No. 10, 01.10.2016, p. 1893-1899.
  • "Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes." Bone Marrow Transplantation In: , 12.09.2016.
  • "Payment and Care for Hematopoietic Cell Transplantation Patients : Toward a Specialized Medical Home for Complex Care Patients." Biology of Blood and Marrow Transplantation In: , 17.07.2016.
  • "Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome." Journal of Clinical Oncology  In: , Vol. 34, No. 16, 01.06.2016, p. 1864-1871.
  • "Mesenchymal stromal cells : Potential roles in graft-versus-host disease prophylaxis and treatment." Transfusion In: , Vol. 56, No. 4, 01.04.2016, p. 9S-14S.
  • "Erratum : Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: A CIBMTR infection and immune reconstitution analysis (Bone Marrow Transplantation (2016) 51 (277-282) DOI:10.1038/bmt.2015.263)." Bone Marrow Transplantation In: , Vol. 51, No. 2, 01.02.2016, p. 322.
  • "Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT : A CIBMTR infection and immune reconstitution analysis." Bone Marrow Transplantation In: , Vol. 51, No. 2, 01.02.2016, p. 277-282.
  • "Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia : A CIBMTR Cohort Analysis." Biology of Blood and Marrow Transplantation  In: , 22.12.2015.
  • "Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia." Biology of Blood and Marrow Transplantation  In: , 16.12.2015.

Additional information

Edit profile